N/A
Completed N=39
Identifying Ideal Reimbursement "Dose" to Reduce Clinical Trial-related Financial Toxicity
Source: ClinicalTrials.gov NCT05871125 ↗Enrolled (actual)
39
Serious AEs
0.0%
Results posted
May 2026
Primary outcomePrimary: Number of Patients Who Receive All Reimbursements and Who Complete Follow-up Surveys (Overall Feasibility of Intervention) — 33; 0 Participants
Summary
The goal of this clinical trial is to explore the feasibility and preliminary impact of a pilot financial reimbursement intervention for women with breast cancer living in the Deep South who are eligible for a clinical trial. The main questions it aims to answer are:
1. Can we recruit and retain patients on a clinical trial to a reimbursement study?
2. What is the preliminary impact of participation in a reimbursement study on patient financial hardship?
Participants will receive a monthly reimbursement to compensate for their trial-incurred expenses. Researchers will use surveys and interviews to explore the impact of receiving reimbursement on trial-related outcomes and financial hardship for participating patients.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Number of Patients Who Receive All Reimbursements and Who Complete Follow-up Surveys (Overall Feasibility of Intervention) |
33; 0 | — |
Eligibility Criteria
Inclusion Criteria
- Participants will be women with breast cancer currently enrolled in the Investigation of Serial studies to Predict Your Therapeutic Response with Imaging and Molecular AnaLysis (I-SPY TRIAL 2) at the UAB Medical Oncology Clinic.
Exclusion Criteria
- Non-English speakers
- Males
- Females without cancer
- Female cancer patients not enrolled in the I-SPY TRIAL 2
Data sourced from ClinicalTrials.gov (NCT05871125). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.